Get started
Author

Roswitha Schumacher‐Kuckelkorn

Observed names: R. Schumacher-Kuckelkorn, Roswitha Schumacher-Kuckelkorn, Schumacher-Kuckelkorn, R., Schumacher‐Kuckelkorn, Roswitha
OpenAlex ID: A5113893344
Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence*
2016 · Roswitha Schumacher‐Kuckelkorn, Ruth Volland, et al. · Pediatric Blood & Cancer · 70
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
2020 · F. Berthold, A. Faldum, et al. · Annals of Oncology · 64
PDF
Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow
2005 · Katrien Swerts, Peter F. Ambros, et al. · Journal of Histochemistry & Cytochemistry · 50
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma
2015 · Esther M. van Wezel, Janine Stutterheim, et al. · Pediatric Blood & Cancer · 24
Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma
2020 · Lieke M. J. van Zogchel, Esther M. van Wezel, et al. · JCO Precision Oncology · 22
PDF
Lacking immunocytological GD2 expression in neuroblastoma: Report of 3 cases
2005 · Roswitha Schumacher-Kuckelkorn, Barbara Hero, et al. · Pediatric Blood & Cancer · 19
Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients
2016 · Esther M. van Wezel, Boris Decarolis, et al. · European Journal of Cancer · 16
PDF
The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma
2020 · Roswitha Schumacher‐Kuckelkorn, Ayad Atra, et al. · Pediatric Blood & Cancer · 6
PDF
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study
2024 · Lieke M. J. van Zogchel, Boris Decarolis, et al. · Journal of Experimental & Clinical Cancer Research · 5
PDF
Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study
2025 · Nina U. Gelineau, Lieke M.J. van Zogchel, et al. · JCO Precision Oncology · 1
Minimal Bone Marrow Disease Is Frequently Detected in Localized Neuroblastoma Patients
2015 · E. van Wezel, Boris Decarolis, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln)
Works count: 17
Citation count: 277
H-index: 7
I10-index: 7
Year
Topic
Type